Full Breakdown
Novo Rebrands as “Novo” in Bid to Reclaim Obesity-Drug Lead
By Drooid · · How we work
Core Event
In mid-September 2026 the Danish drugmaker announced it will use the single name “Novo” for day-to-day activities, while retaining “Novo Nordisk A/S” as the legal entity. The rebrand is anchored by the slogan “Lasting Health Starts Now,” a visual identity that keeps the historic Apis bull logo, and a cultural program called “The Novo Way.” Details will be given at a Capital Markets Day in London on September 21, 2026.
Background & Context
Novo Nordisk’s U.S. obesity-drug share fell behind Eli Lilly, which held 60.9 % of the market in Q2 2026 versus Novo’s 38.8 % (IQVIA). Setbacks include three discontinued Phase 3 trials of the cardiovascular candidate ziltivekimab and the obesity combo CagriSema missing non-inferiority to tirzepatide in the REDEFINE 4 study. Semaglutide, the basis of Ozempic and Wegovy, faces patent expirations in Europe and the United States in the early-to-mid 2030s.
Data & Statistics
- Market share (Q2 2026): 38.8 % Novo vs. 60.9 % Lilly.
- Share-price decline YTD: reported at roughly 15 %; one source cites 12 %.
- Oral Wegovy: >3 million U.S. prescriptions within five months of its January launch; Q2 sales 3.2 billion DKK (? $494 million).
- Pipeline failures: three ziltivekimab trials discontinued; CagriSema weight-loss result 23 % vs. 25.5 % for tirzepatide.
- Employees: >67,000 worldwide.
Official Statements & Responses
Executive vice-president of People, Organisation and Corporate Affairs Tania Sabroe said the updated culture will “allow us to move forward with focus and speed” and that the rebranding “strengthen[s] our competitive advantage and consolidate our role as a trusted partner.” The company outlined four cultural pillars—customer obsession, competitiveness, clarity, and care & integrity—under “The Novo Way.”
Conflicting Reports & Gaps
Sources differ on the YTD share-price decline: CNBC and others report 15 %, while biggo notes 12 %. No definitive explanation is provided.
Verbatim Quotes
- “Our updated culture will allow us to move forward with focus and speed, and our rebranding ensures that we present ourselves with relevance and distinction in all areas: medicines, alliances, marketing, and stakeholder relations. Together, this will strengthen our competitive advantage and consolidate our role as a trusted partner in the healthcare sector,” — Tania Sabroe.
What’s Next
- September 15, 2026: Town-hall meeting for staff ahead of the Capital Markets Day.
- September 21, 2026: Capital Markets Day in London, where Novo will detail its rebrand, cultural shift, and pipeline strategy.